Gallant Interviewed by BioWorld

August 2021

Our Corporate Finance Partner Mr Wilson Ko was interviewed by BioWorld on the potential introduction in Hong Kong of a listing regime for special purpose acquisition companies (“SPAC”). BioWorld is a leading pharmaceutical and medical technology publication.

SPAC is a fundraising strategy which recently boomed in popularity in the United States and prompted Asian regulators to seriously explore formulating a localised mechanism to tap into the SPAC market. In March 2021, Hong Kong’s Financial Secretary Mr Paul Chan said that city’s regulators were giving SPAC listing a serious thought.

For details of the interview and BioWorld’s detailed analysis, please CLICK HERE (available in English only).